Serum-based tracking of de novo initiated liver cancer progression reveals early immunoregulation and response to therapy.

Subleski, Jeff J; Scarzello, Anthony J; Alvord, W Gregory; Jiang, Qun; Stauffer, Jimmy K; Kronfli, Anthony; Saleh, Bahara; Back, Timothy; Weiss, Jonathan M; Wiltrout, Robert H

Subleski, Jeff J; Scarzello, Anthony J; Alvord, W Gregory; Jiang, Qun; Stauffer, Jimmy K; Kronfli, Anthony; Saleh, Bahara; Back, Timothy; Weiss, Jonathan M; Wiltrout, Robert H.

Afiliação

Subleski JJ; Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, United States.
Scarzello AJ; Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, United States.
Alvord WG; Statistical Consulting, Data Management Services, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, United States.
Jiang Q; Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, United States.
Stauffer JK; Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, United States.
Kronfli A; Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, United States.
Saleh B; Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, United States.
Back T; Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, United States.
Weiss JM; Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, United States.
Wiltrout RH; Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, United States. Electronic address: wiltrour@mail.nih.gov.

J Hepatol ; 63(5): 1181-9, 2015 Nov.

Article em En | MEDLINE | ID: mdl-26143441

Assuntos

Adenoma de Células Hepáticas/imunologia; Linfócitos T CD8-Positivos/imunologia; Carcinoma Hepatocelular/imunologia; Imunidade Celular; Neoplasias Hepáticas Experimentais/imunologia; Luciferases/sangue; Proteínas Recombinantes/uso terapêutico; Adenoma de Células Hepáticas/tratamento farmacológico; Adenoma de Células Hepáticas/patologia; Animais; Apoptose; Carcinoma Hepatocelular/tratamento farmacológico; Carcinoma Hepatocelular/patologia; Progressão da Doença; Hepatócitos/patologia; Imuno-Histoquímica; Marcação In Situ das Extremidades Cortadas; Interleucina-12/uso terapêutico; Interleucina-18/uso terapêutico; Neoplasias Hepáticas/tratamento farmacológico; Neoplasias Hepáticas/imunologia; Neoplasias Hepáticas/patologia; Neoplasias Hepáticas Experimentais/tratamento farmacológico; Neoplasias Hepáticas Experimentais/patologia; Imageamento por Ressonância Magnética; Camundongos; Camundongos Endogâmicos C57BL; Transdução de Sinais

Palavras-chave

Gaussia Luciferase; HCA; HCC; Real-time tracking; Sleeping Beauty Transposition; Treatment

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Recombinantes / Adenoma de Células Hepáticas / Carcinoma Hepatocelular / Linfócitos T CD8-Positivos / Imunidade Celular / Neoplasias Hepáticas Experimentais / Luciferases Tipo de estudo: Prognostic_studies / Screening_studies Limite: Animals Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google